Biohaven's BHV-1510 Shows 100% Response Rate in Endometrial Cancer Trial

Biohaven's (BHVN) BHV-1510 cancer drug shows impressive response rates in lung, endometrial, and bladder cancers with fewer side effects than similar treatments.